Rallybio Corporation (RLYB) Bundle
Understanding Rallybio Corporation (RLYB) Revenue Streams
Understanding Rallybio Corporation’s Revenue Streams
The primary revenue source for Rallybio Corporation is through collaboration and license agreements. In the three months ended September 30, 2024, the company reported collaboration and license revenue of $299,000, a significant increase from $0 in the same period of 2023. This revenue growth is attributed to a new collaboration agreement with Johnson & Johnson initiated in the second quarter of 2024.
For the nine months ended September 30, 2024, the company reported total collaboration and license revenue of $598,000, again showing growth from $0 in the same period of 2023.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for collaboration and license revenue is calculated as follows:
- For the three months ended September 30, 2024: Growth Rate = (299 - 0) / 0 = Infinite (from $0 to $299,000)
- For the nine months ended September 30, 2024: Growth Rate = (598 - 0) / 0 = Infinite (from $0 to $598,000)
Contribution of Different Business Segments to Overall Revenue
As of September 30, 2024, the entire revenue of $299,000 for the quarter and $598,000 for the nine-month period is derived solely from collaboration and license revenue. There have been no product sales reported, as the company has not commercialized any products to date.
Analysis of Significant Changes in Revenue Streams
The notable change in revenue for Rallybio Corporation is the introduction of collaboration and license revenue in 2024, stemming from the agreement with Johnson & Johnson. This marks a pivotal shift from previous years where the company reported $0 in revenue. The following table summarizes the revenue figures:
| Period | Collaboration and License Revenue | Total Revenue |
|---|---|---|
| Q3 2024 | $299,000 | $299,000 |
| Q3 2023 | $0 | $0 |
| 9 Months Ended 2024 | $598,000 | $598,000 |
| 9 Months Ended 2023 | $0 | $0 |
This revenue evolution indicates a strategic move towards establishing collaborative partnerships for research and development, reflecting the company’s focus on advancing its product candidates.
A Deep Dive into Rallybio Corporation (RLYB) Profitability
Profitability Metrics
Gross profit, operating profit, and net profit margins:
For the nine months ended September 30, 2024, the total revenue was $598,000, with total operating expenses amounting to $49.5 million. This resulted in a loss from operations of $(48.9 million). The net loss for the same period was $(46.7 million), translating to a net loss per share of $(1.08) .
The gross profit margin can be calculated as follows:
- Total Revenue: $598,000
- Cost of Goods Sold: $0 (no products sold)
- Gross Profit: $598,000
- Gross Profit Margin: 100%
Operating profit margin for the nine months ended September 30, 2024 is:
- Operating Profit: $(48.9 million)
- Operating Profit Margin: -81.66% (calculated as Loss from Operations divided by Total Revenue)
Trends in profitability over time:
Comparing to the nine months ended September 30, 2023, where the net loss was $(54.3 million), there has been an improvement in profitability metrics with a reduction in the net loss by $7.6 million .
Comparison of profitability ratios with industry averages:
The industry average net profit margin for biotechnology companies is typically negative due to high research and development costs. The latest data shows that the average net profit margin in the biotech sector is around -25%, which indicates that the company is performing worse than the average .
Analysis of operational efficiency:
Research and development expenses for the nine months ended September 30, 2024, were $34.1 million, down from $37.6 million in the same period of 2023, reflecting a cost reduction of $3.5 million . General and administrative expenses also decreased from $20.2 million to $15.4 million, a reduction of $4.8 million .
The following table summarizes the operating expenses and net loss over the two periods:
| Metric | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Total Revenue | $598,000 | $0 | $598,000 |
| Research and Development | $34,122,000 | $37,620,000 | $(3,498,000) |
| General and Administrative | $15,364,000 | $20,200,000 | $(4,836,000) |
| Total Operating Expenses | $49,486,000 | $57,820,000 | $(8,334,000) |
| Net Loss | $(46,731,000) | $(54,322,000) | $(7,591,000) |
Overall, the company has shown improved operational efficiency, with significant reductions in both research and administrative expenses, contributing to a lower net loss compared to the previous year .
Debt vs. Equity: How Rallybio Corporation (RLYB) Finances Its Growth
Debt vs. Equity: How Rallybio Corporation Finances Its Growth
Debt Levels
As of September 30, 2024, Rallybio Corporation reported total liabilities of $8.2 million, which includes current liabilities of $8.2 million and no long-term debt. The total liabilities were a decrease from $9.4 million reported as of December 31, 2023.
Debt-to-Equity Ratio
The debt-to-equity ratio for Rallybio Corporation as of September 30, 2024, is calculated as total liabilities divided by total stockholders' equity. With total liabilities of $8.2 million and total stockholders' equity of $70.8 million, the debt-to-equity ratio is approximately 0.12. This is significantly lower than the industry average for biotechnology companies, which typically ranges between 0.3 to 0.5.
Recent Debt Issuances and Credit Ratings
Rallybio Corporation has not issued any long-term debt as of the latest reporting date. The company primarily relies on equity financing for its operations. As of September 30, 2024, they had cash, cash equivalents, and marketable securities totaling $75.1 million. The company has not been assigned a credit rating due to the absence of debt obligations.
Equity Financing
Rallybio Corporation has historically funded its operations through equity financing. From inception prior to its IPO, the company raised approximately $182.5 million through equity financings. In its IPO in August 2021, it raised $83.0 million by issuing 7,130,000 shares at a price of $13.00 per share. In April 2024, the company sold 3,636,363 shares at $1.82 per share, raising approximately $6.6 million.
Table: Summary of Debt and Equity Financing Activities
| Activity | Amount (in millions) | Date |
|---|---|---|
| Total Liabilities | $8.2 | September 30, 2024 |
| Total Stockholders' Equity | $70.8 | September 30, 2024 |
| Debt-to-Equity Ratio | 0.12 | September 30, 2024 |
| Cash and Cash Equivalents | $75.1 | September 30, 2024 |
| IPO Proceeds | $83.0 | August 2021 |
| Recent Share Sale (April 2024) | $6.6 | April 2024 |
Balancing Debt and Equity Financing
Rallybio Corporation maintains a conservative approach to financing, opting for equity over debt to minimize financial risk. This strategy allows the company to fund its research and development initiatives while avoiding the burden of interest payments associated with debt financing. As of the latest reporting date, the company does not have any outstanding long-term debt, which positions it favorably for future growth and investment opportunities.
Assessing Rallybio Corporation (RLYB) Liquidity
Assessing Liquidity and Solvency
The liquidity and solvency of a company are critical indicators of its financial health, especially for a clinical-stage biotechnology firm. This section explores the liquidity position through various metrics and cash flow analysis.
Current and Quick Ratios
As of September 30, 2024, the current assets of the company were reported at approximately $75.1 million, while the current liabilities were $8.2 million. This results in a current ratio of:
Current Ratio = Current Assets / Current Liabilities = $75.1 million / $8.2 million ≈ 9.15
The quick ratio, which excludes inventory from current assets, is calculated based on similar figures, leading to a quick ratio of:
Quick Ratio = (Current Assets - Inventory) / Current Liabilities = $75.1 million / $8.2 million ≈ 9.15
Both ratios indicate a strong liquidity position, suggesting that the company can easily cover its short-term obligations.
Analysis of Working Capital Trends
Working capital, calculated as current assets minus current liabilities, stood at:
Working Capital = Current Assets - Current Liabilities = $75.1 million - $8.2 million = $66.9 million
This significant positive working capital reflects the company’s capability to manage its operational needs effectively. The trend has shown improvement compared to previous periods, indicating a robust liquidity position.
Cash Flow Statements Overview
The cash flow statement provides a clearer picture of the company's liquidity. For the nine months ended September 30, 2024, the cash flows were as follows:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | ($39,420) | ($48,620) |
| Net Cash Provided by Investing Activities | $35,065 | $10,749 |
| Net Cash Provided by Financing Activities | $5,181 | $71 |
| Net Increase (Decrease) in Cash and Cash Equivalents | $826 | ($37,800) |
This cash flow overview shows a reduction in cash outflow from operating activities, reflecting improved efficiency in managing expenses. The substantial cash inflow from investing activities indicates active management of marketable securities.
Potential Liquidity Concerns or Strengths
Despite the positive liquidity indicators, there are potential concerns regarding future cash needs. As of September 30, 2024, the accumulated deficit reached $282.0 million, indicating significant historical losses. Future funding requirements for clinical trials and operational expenses remain a critical consideration, as the company projects ongoing losses while advancing its product candidates. The company will need to raise additional capital through equity or debt financing to sustain operations beyond its current liquidity resources.
Is Rallybio Corporation (RLYB) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the financial metrics for the company are as follows:
| Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | N/A |
| Price-to-Book (P/B) Ratio | 0.37 |
| Enterprise Value-to-EBITDA (EV/EBITDA) Ratio | N/A |
The stock price trends over the last 12 months have shown the following:
| Date | Stock Price |
|---|---|
| September 2023 | $3.00 |
| December 2023 | $2.50 |
| March 2024 | $1.82 |
| June 2024 | $2.00 |
| September 2024 | $1.82 |
As of September 30, 2024, the company has not declared any dividends, resulting in a dividend yield of 0%. The payout ratio is also 0% due to no dividends being issued.
Analyst consensus on the stock valuation is mixed:
- Buy: 2 analysts
- Hold: 3 analysts
- Sell: 1 analyst
Recent financial results indicate:
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $11.5 million | $18.4 million |
| Revenue | $0.3 million | $0 million |
| Total Assets | $79.0 million | $115.6 million |
| Accumulated Deficit | $281.98 million | $235.25 million |
The company had cash, cash equivalents, and marketable securities amounting to $75.1 million as of September 30, 2024.
Key Risks Facing Rallybio Corporation (RLYB)
Key Risks Facing Rallybio Corporation
Rallybio Corporation faces a variety of internal and external risks that could impact its financial health significantly. These risks include competition within the biotechnology sector, regulatory changes, and fluctuating market conditions that can affect operational capacity and financial performance.
Internal Risks
As a clinical-stage biotechnology company, Rallybio has not yet commercialized any products. As of September 30, 2024, the company reported an accumulated deficit of $281.976 million. The company has incurred net losses of $46.731 million and $54.322 million for the nine months ended September 30, 2024, and 2023, respectively. Furthermore, operational challenges related to the development of product candidates, including RLYB212 and RLYB116, pose risks to achieving future profitability.
Financial Risks
Rallybio's financial stability is contingent upon its ability to secure additional capital. The company has indicated the need for significant financing to support its ongoing development efforts. As of September 30, 2024, Rallybio had cash, cash equivalents, and marketable securities totaling $75.1 million. The company anticipates that this capital will suffice to fund operations into the middle of 2026; however, unforeseen expenses could accelerate capital depletion.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Accumulated Deficit | As of September 30, 2024, the accumulated deficit stands at $281.976 million. | Potential inability to fund operations leading to further losses. |
| Net Loss | Net losses reported are $46.731 million for the nine months ended September 30, 2024. | Continued losses could impair capital raising efforts. |
| Cash Reserves | Cash, cash equivalents, and marketable securities total $75.1 million. | Insufficient funds may halt development activities. |
Operational Risks
The company has faced operational risks that include the high costs associated with clinical trials and the unpredictability of regulatory approvals. The clinical development process requires substantial investment, and as indicated, the costs to advance any product candidate are significant. Specifically, the anticipated Phase 2 clinical trial for RLYB212 may incur substantial expenses that are hard to predict.
Market Risks
Market conditions can significantly influence Rallybio's financial health. The biotechnology industry is characterized by rapid changes in technology and competition. For instance, competition from other biotechnology firms can hinder market share and pricing strategies. The company’s reliance on collaborations, such as the agreement with Johnson & Johnson, adds another layer of market risk, as these partnerships can be unpredictable.
Mitigation Strategies
Rallybio has outlined several strategies to mitigate these risks, including prioritizing its portfolio and reducing workforce size to conserve capital. The company also aims to secure additional collaborations and licensing agreements to bolster its financial position and expand its operational capabilities.
Future Growth Prospects for Rallybio Corporation (RLYB)
Future Growth Prospects for Rallybio Corporation
Analysis of Key Growth Drivers
The company has recently entered into a collaboration agreement with Johnson & Johnson, which is expected to enhance its revenue streams. This agreement includes an upfront payment of $0.5 million and potential additional payments of up to $0.7 million based on achieving specific milestones related to their research initiatives.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company reported total revenue of $598,000, a significant increase compared to $0 in the same period of 2023. Analysts anticipate that as the company progresses through its clinical trials, particularly the planned Phase 2 clinical trial for RLYB212, revenues could increase substantially if the trials succeed and products become commercially viable.
Strategic Initiatives or Partnerships That May Drive Future Growth
In addition to the Johnson & Johnson collaboration, the company has also focused on reducing operating expenses, which decreased from $57.8 million in the first nine months of 2023 to $49.5 million in the same period of 2024. This strategic cost management, along with the potential for additional partnerships, positions the company to optimize its financial health while pursuing growth opportunities.
Competitive Advantages That Position the Company for Growth
The company has a strong focus on its research and development pipeline, particularly with programs like RLYB212, which has shown promising preliminary results. The ongoing investment in clinical trials is crucial, as the total research and development expenses were $34.1 million for the nine months ended September 30, 2024, compared to $37.6 million in the same period of 2023. This ongoing investment is expected to yield competitive advantages in the biotechnology sector.
| Financial Metric | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Collaboration and License Revenue | $598,000 | $0 | + $598,000 |
| Total Revenue | $598,000 | $0 | + $598,000 |
| Total Operating Expenses | $49.5 million | $57.8 million | - $8.3 million |
| Net Loss | $46.7 million | $54.3 million | + $7.6 million |
| Research and Development Expenses | $34.1 million | $37.6 million | - $3.5 million |
As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $75.1 million, which is projected to support operations into mid-2026. This liquidity will be vital as the company seeks to advance its clinical programs and explore further collaborative opportunities.
Rallybio Corporation (RLYB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Rallybio Corporation (RLYB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Rallybio Corporation (RLYB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Rallybio Corporation (RLYB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.